Browsing Tag
uniQure N.V.
2 posts
uniQure (NASDAQ: QURE) sinks after FDA mandates Phase III trial for Huntington’s therapy AMT-130
uniQure (QURE) plunges after FDA demands a Phase III trial for AMT-130 in Huntington’s disease. What this means for valuation and next steps.
uniQure moves closer to FDA approval as AMT-130 gene therapy shows progress for Huntington’s disease
Find out how uniQure’s AMT-130 regulatory path for Huntington’s disease is evolving after the FDA’s latest feedback on its data sufficiency.